Pfizer vs ALSAC

10-Q Financial Filing Analysis for Pfizer (2026-08-04)

Pfizer Inc. reported its second-quarter 2026 financial results, with total revenues rising 3% year-over-year to $15.03 billion (up 1% operationally). Operational expansion was led by core franchises including Eliquis (+19% operationally to $2.43 billion), Padcev (+23% operationally to $667 million), and the Vyndaqel family (+8% operationally to $1.76 billion), which offset steep declines in COVID-19 product revenues (Paxlovid down 95% operationally to $21 million; Comirnaty down 34% operationally to $261 million). The company reported a net loss attributable to common shareholders of $(248) million for Q2 2026, compared to net income of $2.91 billion in Q2 2025. This downturn was driven by $4.33 billion in pre-tax intangible asset impairment charges (including $3.8 billion for sigvotatug vedotin following unfavorable Phase 3 trial results and $525 million for Oxbryta), alongside $842 million in legal charges, partially offset by a $1.87 billion net gain on the exit of its ViiV Healthcare investment. Pfizer also expanded its enterprise-wide cost realignment and manufacturing optimization programs, targeting total net cost savings of approximately $6.7 billion and $3.0 billion, respectively, through 2029.

• Q2 2026 total revenues reached $15.03 billion, up 3% YoY (5% operational growth excluding COVID-19 products Comirnaty and Paxlovid).
• Net loss attributable to common shareholders was $(248) million, heavily impacted by $4.325 billion in intangible asset impairments ($3.8 billion for IPR&D sigvotatug vedotin and $525 million for Oxbryta) and $842 million in legal charges.
• Pfizer completed the sale of its 11.7% stake in ViiV Healthcare for $1.875 billion in cash proceeds, realizing a pre-tax net gain of $1.870 billion.

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Investor Presentation Released: Pfizer

AI parsed presentation narrative: Pfizer is demonstrating steady execution and financial outperformance by exceeding revenue and EPS expectations despite the decline in COVID-19 product sales. Management's central thesis focuses on maximizing the value of key acquisitions like Seagen and Metsera to drive post-2028 growth through a high single-digit revenue CAGR and a robust pipeline in oncology and obesity. Key tailwinds mentioned: Acquisition Integration Success, Obesity Pipeline Advancement.

St. Jude Newsroom: KDM2B revealed as a selective dependency in high-risk medulloblastoma subgroups

The St. Jude Newsroom page has been updated with several new press releases. Notable additions include: 'KDM2B revealed as a selective dependency in high-risk medulloblastoma subgroups' (09/24/2026), 'Targeting ZMYND8 improves T-cell function and may boost immunotherapy' (09/23/2026), 'U.S. News & World Report ranks St. Jude among top three outstanding pediatric cancer hospitals' (09/15/2026), 'AI-informed AdaptiveFlow redefines large-scale cloud computing for drug discovery' (09/01/2026), 'ALSAC Named to Fast Company's 2026 Best Workplaces for Innovators List' (09/10/2026), and 'Chili's® Announces Historic $150 Million Commitment to St. Jude Children's Research Hospital®' (09/08/2026).

Chili’s® Announces Historic $150 Million Commitment to St. Jude Children’s Research Hospital®

Chili’s® Grill & Bar made a new pledge to help raise $150 million over the next 15 years to help support children and families facing cancer and other life-threatening diseases at St. Jude.